As previously reported, Morgan Stanley analyst David Lebowitz upgraded Alnylam to Overweight from Equal Weight, stating that he expects Onpattro to ultimately exceed the Street's expectations for 2019 given early metrics about the drug's launch. Even modest sequential adds as the year progresses to the 200 patients on the drug at year-end 2018 should put it on track to beat his 2019 sales estimate of $105M, as well as consensus of $94M, said Lebowitz. He also expects positive news flow from the company's late stage pipeline, particularly Givosiran and Lumasiran. Lebowitz raised his price target on Alnylam shares to $122 from $81.

ProQR Therapeutics (PRQR) announced the Annual General Meeting, AGM, of Shareholders will take place on Wednesday, May 22, 2024 at the offices of Allen & Overy LLP, in Amsterdam, the Netherlands. As part of the AGM, Martin Maier, PhD, is nominated for appointment as a non-executive Board Member for a period of four years. Dr. Maier is Senior Vice President Research heading the Oncology group at Alnylam Pharmaceuticals (ALNY).